Artery Research

<Previous Article In Issue
Download article (PDF)
Next Article In Issue>
Volume 20, Issue C, December 2017, Pages 103 - 104

P155 CORRELATION OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND S100-A1 ON ARTERIAL STIFFNESS IN NORMOTENSIVE PATIENTS WITH DIABETES

Authors
Patricia Quezada Fernandez1, 2, Fernando Grover Páez3, 4, 5, Becerra Ramos6, 7, Carlos6, 7, Jhonatan Trujillo Quiros6, Walter Trujillo Rangel6, Sánchez Rodríguez Sánchez Rodríguez6, David Cardona Müller6, 8, Mayra Jimenez Cázarez6
1Experimental Therapeutic and Clinic Institute, Physiology Department of the University of Guadalajara, Mexico
2PNPC, National Council of Science and Technology (CONACYT), Mexico
3University of Guadalajara, Physiology Department of the University of Guadalajara, Mexico
4Experimental Therapeutic and Clinic Institute, University of Guadalajara, Mexico
5National System of Researchers Grade 1, National Council of Science and Technology, Mexico
6Vascular Mechanics Laboratory, Experimental Therapeutic and Clinic Institute, Physiology Department, Health Sciences University Center, University of Guadalajara, Mexico
7National System of Researchers, National Council of Science and Technology (CONACYT), Mexico
8National Council of Cardiology, Mexico
Available Online 6 December 2017.
DOI
10.1016/j.artres.2017.10.176How to use a DOI?
Abstract

Background: Accumulation of advanced glycation end products (AGEs) are involved in several pathophysiological processes in the vessel wall, that may cause premature atherosclerosis and arterial stiffening (1). A soluble form of RAGE (sRAGE), which is a splice variant of full-length RAGE has been considered to be protective against diseases originating from RAGE activation since sRAGE can bind and sequester RAGE ligands and reduce RAGE activation (2). S100A1 is the most abundant calcium-binding protein in myocardial tissue and is a major determinant of cardiac function. This circulating ligand of the RAGE is known as a pro-inflammatory factor in diabetes. Aberrant expression levels of S100A1 surfaced as molecular key defects, driving the pathogenesis of cardiovascular diseases (3).

Objective: This study was design to explore the relationship between serum levels of sRAGE and S100A1 on arterial stiffness in non-hypertensive patients with diabetes.

Methods: Using a cross-sectional design, a total of 20 non-hypertensive patients with diabetes were recruited. A fasting blood sample, medical history and arterial stiffness parameters were collected.

Results: In bivariate analysis, sRAGE positively correlated with time evolution of diabetes (r = 0.503, p < 0.024) and negatively correlated with systolic (r = −0.457, p = 0.043) and diastolic blood pressure (r = −0.527, p = 0.017). S100A1 positively correlated with creatinine (r = 0.724, p < 0.000) and negatively correlated with peripheral and central hemodynamics, including augmentation index (r = −0.469, p = 0.037), as shown in Table 2.

Variables r Spearman p-value
T2DM time evolution −0.203 0.309
HbA1c −0.082 0.780
Creatinine 0.724 0.000*
Systolic Blood pressure −0.487 0.029*
Diastolic Blood pressure −0.456 0.043*
Pulse pressure −0.476 0.034*
Arterial Mean Pressure −0.437 0.054*
Central Systolic Blood −0.452 0.045*
Pressure
Central Diastolic Blood pressure −0.448 0.047*
Aortic Pulse Wave velocity −0.361 0.118
Central pulse pressure −0.035 0.041*
Aortic Augmentation Index −0.469 0.037*

Abreviation: sRAGE, soluble receptor for advanced glycation end products; T2DM, type 2 diabetes mellitus

Table 2.

Correlation of sRAGE with metabolic, hemodynamic and arterial stiffening variables.

Conclusion: This study shows a significant correlation of serum sRAGE and S100-A1 on peripheral and central hemodynamics in non-hypertensive diabetic patients.

Open Access
This is an open access article distributed under the CC BY-NC license.

References

1.M Kozakova and C Palombo, Diabetes mellitus, Arterialwall, and cardiovascular risk assessment, International journal of environmental research and public health, Vol. 13, No. 2, 2016, pp. 201.
2.A Bierhaus, PM Humpert, M Morcos, T Wendt, T Chavakis, B Arnold, et al., Understanding RAGE, the receptor for advanced glycation end products, Journal of molecular medicine, Vol. 83, No. 11, 2005, pp. 876-86.
3.S Duarte-Costa, R Castro- Ferreira, JS Neves, and AF Leite-Moreira, S100A1: a major player in cardiovascular performance, Physiological research, Vol. 63, No. 6, 2014, pp. 669.
<Previous Article In Issue
Download article (PDF)
Next Article In Issue>
Journal
Artery Research
Volume-Issue
20 - C
Pages
103 - 104
Publication Date
2017/12/06
ISSN (Online)
1876-4401
ISSN (Print)
1872-9312
DOI
10.1016/j.artres.2017.10.176How to use a DOI?
Open Access
This is an open access article distributed under the CC BY-NC license.

Cite this article

risenwbib
TY  - JOUR
AU  - Patricia Quezada Fernandez
AU  - Fernando Grover Páez
AU  - Becerra Ramos
AU  - Carlos
AU  - Jhonatan Trujillo Quiros
AU  - Walter Trujillo Rangel
AU  - Sánchez Rodríguez Sánchez Rodríguez
AU  - David Cardona Müller
AU  - Mayra Jimenez Cázarez
PY  - 2017
DA  - 2017/12/06
TI  - P155 CORRELATION OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND S100-A1 ON ARTERIAL STIFFNESS IN NORMOTENSIVE PATIENTS WITH DIABETES
JO  - Artery Research
SP  - 103
EP  - 104
VL  - 20
IS  - C
SN  - 1876-4401
UR  - https://doi.org/10.1016/j.artres.2017.10.176
DO  - 10.1016/j.artres.2017.10.176
ID  - QuezadaFernandez2017
ER  -